ReviewFrontiers in endocrinology2026
Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bile acids (BAs) serve dual roles as lipid-digesting molecules and key signaling mediators in metabolism and immune regulation. This review systematically examines: 1.the molecular mechanisms underlying BA-mediated regulation of glucolipid m5etabolism and energy expenditure; 2.host- and microbiota-driven BA modifications (e.g., 3-acylation); 3. therapeutic targeting of BA signaling pathways (FXR/TGR5). We highlight emerging strategies, including novel BA modifications, microbiota interventions, and BA-targeted therapies, which reshape BA homeostasis and show therapeutic potential for metabolic, digestive, hepatobiliary, and neoplastic diseases. Furthermore, we emphasize the central role of BA modifications in metabolic regulation and their pathological implications. Advances in multi-omics and AI-driven approaches deepen mechanistic insights and accelerate the translation of BA-based interventions into clinical practice. Most of the findings discussed in this review are derived from preclinical studies (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.